Latest News

Mirum Pharmaceuticals et Incyte annoncent l’autorisation par la FDA américaine d’Atebrioz™ (zilurgisertib) pour les patients adultes et pédiatriques atteints de fibrodysplasie ossifiante progressive

Mirum Pharmaceuticals und Incyte melden FDA-Zulassung für Atebrioz™ (Zilurgisertib) für erwachsene und pädiatrische Patienten mit Fibrodysplasia ossificans progressiva

Mirum Pharmaceuticals e Incyte anuncian que Atebrioz™ (zilurgisertib) obtuvo la aprobación de la FDA de los EE. UU. para pacientes adultos y pediátricos con fibrodisplasia osificante progresiva

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages York Space Systems Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YSS

Did Zeta Global Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did BellRing Brands, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did CVS Health Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Did Krispy Kreme, Inc. Insiders Breach their Fiduciary Duties to Shareholders?